WST - West Pharmaceutical Services, Inc.
(NaN%)
SNP 500
Sell
Strong Growth but Declining●Stock Price Very High
75%
based on last 5 year data.
Income Statement is STRONG
Revenue Growth is 2.18%
Operating Income Growth is -7.9%
Net Income Growth is 1.28%
Earnings Per Share (EPS) Growth is 1.94%
Net Margin is 20.12%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 2.88
Debt Ratio is 0.25
Current Debt to Net Income Ratio is 0.23
Total Debt to Total Assets Ratio is 0.05
Cash Flow is STRONG
Cash from Operations Growth is 7.25%
Capital Expenditure is High
Net Increase in Cash is Negative
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
West Pharmaceutical Services, Inc. (WST) - www.westpharma.com
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With almost 10,000 team members across 50 sites worldwide, West helps support its customers by delivering over 40 billion components and devices each year.Exchange - NEW YORK STOCK EXCHANGE INC.
Industry - Medical Laboratories
Sector - Health Care and Social Assistance
CEO - Eric Green
Employees - 10,700
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2024 and future.
Know the Stock © 2024 and future.